Skip to content
Tuesday, January 31, 2023
Latest:
  • KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
  • The Valens Company to Hold Conference Call to Discuss Financial Results for the First Quarter of 2021
  • AlumiFuel Reduces the Authorized Number of Shares
  • Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans
  • FACT, Inc. Announces Patricia Trompeter as CEO
Biotech Research Report

Biotech Research Report

Know First, Act First

  • Covid-19
  • General
  • Cannabis
  • Fiscal & Financing
  • Pharmaceutical
  • Trending

Pharmaceutical

BIOTCHNO Pharmaceutical 

Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

January 26, 2021April 15, 2021 vanessa

Canada NewsWire BOSTON and BEIJING, Jan. 26, 2021/CNW/ —Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for

Read more
BIOTCHNO Pharmaceutical 

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

January 11, 2021May 24, 2021 vanessa

Eisai to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium TOKYO, Jan 12, 2021 – (JCN Newswire) – Eisai

Read more
BIOTCHNO Pharmaceutical 

Bronya Climate Shield Lab Results Indicate Fire Retardant Solution to OSB I-Joist Manufacturer

January 7, 2021April 15, 2021 vanessa

Bronya Climate Shield Lab Results Indicate Fire Retardant Solution to OSB I-Joist Manufacturer  Toronto, Ontario–(Newsfile Corp. – January 7, 2021)

Read more
BIOTCHNO Pharmaceutical 

Mountain Valley MD Files for Acceleration of Patent Examination for Solubilized Ivermectin

December 24, 2020April 15, 2021 vanessa

Canada NewsWire VANCOUVER, BC,Dec. 24, 2020/CNW/ –Mountain Valley MD Holdings Inc.(the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased

Read more
BIOTCHNO Pharmaceutical 

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

December 15, 2020April 15, 2021 vanessa

LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020/CNW Telbec/ – Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”),

Read more
BIOTCHNO Pharmaceutical 

Mountain Valley MD Confirms 800% Increase in Ivermectin Absorption with Solubilization Technology in Pre-Clinical Trial

December 10, 2020April 15, 2021 vanessa

VANCOUVER, BC,Dec. 10, 2020/CNW/ –Mountain Valley MD Holdings Inc.(the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) is pleased to announce

Read more
BIOTCHNO Pharmaceutical 

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET(TM) Immunotherapy Candidate for Patients with Solid Tumors

December 1, 2020April 15, 2021 vanessa

Canada NewsWire WALTHAM, Mass., Dec. 1, 2020 Merck executes option to license its first immunotherapy candidate from the companies’ 2018

Read more
BIOTCHNO Pharmaceutical 

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte’s 2020 Technology Fast 500(TM)

November 25, 2020May 24, 2021 vanessa

Canada NewsWire VICTORIA, BC, Nov. 25, 2020 VICTORIA, BC,Nov. 25, 2020/CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV:

Read more
BIOTCHNO Pharmaceutical 

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

November 24, 2020April 15, 2021 vanessa

Canada NewsWire NYON, Switzerland, Nov. 24, 2020 NYON, Switzerland, Nov. 24, 2020/CNW/ — MedAlliance has announced completion of patient enrolment

Read more
BIOTCHNO Pharmaceutical 

PostEra and NeuroLucent collaborate on identifying small-molecule therapeutics for Alzheimer’s disease

October 25, 2020April 15, 2021 vanessa

Canada NewsWire SAN FRANCISCO and NORTH CHICAGO, Ill., Nov. 25, 2020 SAN FRANCISCOandNORTH CHICAGO, Ill.,Nov. 25, 2020/CNW/ —PostEra, a biotechnology

Read more
  • ← Previous

Cannabis

SiliCycle signs a Letter of Intent with the Société Québécoise du Cannabis (SQDC)
BIOTCHNO Cannabis 

SiliCycle signs a Letter of Intent with the Société Québécoise du Cannabis (SQDC)

February 15, 2021April 14, 2021 Bachittar

SiliCycle signs a Letter of Intent with the Société Québécoise du Cannabis (SQDC) QUEBEC CITY , Dec. 15, 2020 /CNW

Nutra Pharma Provides Updates on Progress of their Nerve Agent Countermeasures
BIOTCHNO Cannabis 

Nutra Pharma Provides Updates on Progress of their Nerve Agent Countermeasures

November 18, 2020April 19, 2021 vanessa
  • Disclaimer
  • Privacy Policy
TD Media LLC dba Life Water Media
1415 South Voss Road Suite 110-431 Houston, TX 77057